Significant reductions in PTSD symptoms were identified at posttreatment ( Cohen d = 0.78 , P < .05 ) and maintained at 3 - and 6-month follow-up ( d = 0.73 , P < .05 and d = 0.76 , P < .05 , respectively ) .